Business
FDA throws wet blanket on Mesoblast’s treatment for bone marrow transplant condition – Business News Australia
Before pivoting to find a treatment for critically ill COVID-19 patients suffering from severe acute respiratory distress syndrome (ARDS), Mesoblast’s (ASX: MSB, NASDAQ: MESO) most advanced business centred on an entirely different ailment.
Before pivoting to find a treatment for critically ill COVID-19 patients suffering from severe acute respiratory distress syndrome (ARDS), Mesoblast’s (ASX: MSB, NASDAQ: MESO) most advanced business centred on an entirely different ailment.
The Melbourne-based company has sought US regulatory approval for its stem cell-based product remestemcel-L in treating graft versus host disease (GvHD) – a potentially life-threatening condition that some people experience after receiving a bone marrow tran…
-
General23 hours agoAxe falls on loggers’ plan to avoid battle over gliders
-
General21 hours agoBill Shorten believes Peter Dutton’s work-from-home policy backflip will cost him at election time
-
Noosa News21 hours ago$100 Million Cavill Avenue revamp set to reshape Surfers Paradise
-
General22 hours agoOh, for the good old days? • Inside Story